phrykt

Abbott Laboratories (ABT): who owns it and who trades it

As of Nov 16, 2026, ABT insiders reported 12 open-market sales worth $47.9M and 6 purchases worth $4.4M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Robert B Ford (CEO), with $46.2M. 10 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Abbott Laboratories

From the latest filings

Overall: more selling than buying. Insiders, famous investors and Congress mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ABT

2,951 funds and institutions reported ABT shares worth $125B at the end of Q2 2026, about 80% of the company. The largest holder is BlackRock, Inc. with 8.8%.

Funds and institutions (13F) 80%Everyone else 20%

10 largest owners, by share of the company

BlackRock, Inc.8.8%
Vanguard Capital Management LLC6.6%
State Street Corp4.7%
Charles Schwab Investment Management Inc3.4%
Vanguard Portfolio Management LLC2.8%
Geode Capital Management, LLC2.3%
Capital Research Global Investors2.1%
Capital International Investors2.0%
Morgan Stanley1.5%
Norges Bank1.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.152.56M8.82%$13.8B+5%
Vanguard Capital Management LLC113.75M6.57%$10.3B+1%
State Street Corp80.93M4.68%$7.3B+2%
Charles Schwab Investment Management Inc59.67M3.45%$5.4B+31%
Vanguard Portfolio Management LLC49.02M2.83%$4.4B+2%
Geode Capital Management, LLC39.22M2.27%$3.5B+0%
Capital Research Global Investors36.91M2.13%$3.3B-26%
Capital International Investors34.65M2.00%$3.1B-8%
Morgan Stanley26.61M1.54%$2.4B-12%
Norges Bank23.35M1.35%$2.1B–
T. Rowe Price Associates22.79M1.32%$2.1B+32%
Franklin Resources Inc18.81M1.09%$1.7B-6%
Northern Trust Corp18.27M1.06%$1.7B-6%
Bank of America Corp17.67M1.02%$1.6B-8%
Goldman Sachs Group Inc16.76M0.97%$1.5B+16%
Deutsche Bank Ag\16.71M0.97%$1.5B+19%
Wells Fargo & Company15.18M0.88%$1.4B-5%
JPMorgan Chase & Co15.10M0.87%$1.4B–
State Farm Mutual Automobile Insurance Co13.59M0.79%$1.2BNo change
FMR LLC (Fidelity)13.42M0.78%$1.2B+24%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ABT insiders reported $4.4M of open-market purchases and $47.9M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$4.4M
6 trades, 4 people
Sales, 12 months
$47.9M
12 trades, 7 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 5, 2026
Filed Nov 6, 2026

Purchases and sales by month

$46.8M$46.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 5, 2026Mary K MorelandVice presidentSale3,500$116.00$406KForm 4
Sep 2, 2026John A. Mccoy Jr.Vice presidentSale27$109.54$3KForm 4
Aug 25, 2026Robert B FordCEOSale218,535$115.57$25.3MForm 4
Aug 25, 2026Robert B FordCEOSale180,297$116.19$20.9MForm 4
Aug 11, 2026Louis H. MorroneVice presidentSale5,850$109.83$643KForm 4
May 7, 2026John G StrattonDirectorPurchase2,000$86.82$174KForm 4
Apr 27, 2026Daniel J StarksDirectorPurchase10,000$92.65$926KForm 4
Apr 23, 2026Philip P BoudreauCFOPurchase2,200$91.50$201KForm 4
Mar 2, 2026Eric ShroffVice presidentSale709$115.58$81.9KForm 4
Mar 2, 2026Daniel Gesua Sive SalvadoriVice presidentSale885$115.58$102KForm 4
Mar 2, 2026Louis H. MorroneVice presidentSale1,144$115.58$132KForm 4
Mar 2, 2026Mary K MorelandVice presidentSale613$115.58$70.9KForm 4
Mar 2, 2026John A. Mccoy Jr.Vice presidentSale585$115.58$67.6KForm 4
Mar 2, 2026Elizabeth C. CushmanVice presidentSale263$115.58$30.4KForm 4
Feb 4, 2026Daniel J StarksDirectorPurchase5,033$108.33$545KForm 4
Feb 4, 2026Daniel J StarksDirectorPurchase4,967$109.14$542KForm 4
Jan 23, 2026Robert B FordCEOPurchase18,800$107.13$2MForm 4
Nov 25, 2025Eric ShroffVice presidentSale1,586$128.02$203KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Robert B FordCHAIRMAN AND CEO, Director$2M$46.2MAug 25, 2026
Daniel J StarksDirector$2M–Apr 27, 2026
Louis H. MorroneEXECUTIVE VICE PRESIDENT–$775KAug 11, 2026
Mary K MorelandEXECUTIVE VICE PRESIDENT–$477KNov 5, 2026
Eric ShroffSenior Vice President–$285KMar 2, 2026
Philip P BoudreauEVP AND CFO$201K–Apr 23, 2026
John G StrattonDirector$174K–May 7, 2026
Daniel Gesua Sive SalvadoriEVP AND GROUP PRESIDENT–$102KMar 2, 2026
John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLER–$70.6KSep 2, 2026
Elizabeth C. CushmanEVP, GC AND SECRETARY–$30.4KMar 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ABT short interest

Low short interest. 1.1% of ABT shares are sold short: about 1 share in 91. Over the last 12 reports the number of shares short went down 18%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 19.06M ABT shares were sold short, 1.1% of the shares outstanding, up 9.6% from the report before. At the average daily volume of 9.96M shares, buying them all back would take about 1.9 trading days (days to cover).

Shares short, % of all shares

1.10%May 15Oct 301.53%

Days to cover

1.9May 15Oct 303.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202619.06M1.10%+10%9.96M1.9
Oct 15, 202617.39M1.00%+28%9.77M1.8
Sep 30, 202613.63M0.79%-32%9.34M1.5
Sep 15, 202619.91M1.15%-10%7.73M2.6
Aug 31, 202622.13M1.28%+9%8.30M2.7
Aug 14, 202620.38M1.18%-10%7.13M2.9
Jul 31, 202622.62M1.31%-9%13.63M1.7
Jul 15, 202624.85M1.44%+6%11.61M2.1
Jun 30, 202623.39M1.35%+6%15.81M1.5
Jun 15, 202621.97M1.26%-0%12.40M1.8
May 29, 202622.04M1.27%-5%11.37M1.9
May 15, 202623.22M1.33%+3%13.67M1.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded ABT

Since Nov 17, 2024, 19 members of Congress reported 17 purchases and 28 sales of ABT. The latest was a sale by Pete Sessions on Oct 2, 2026, reported Oct 27, 2026.

Purchases 17Sales 28

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Oct 2, 2026Pete Sessions (R-TX)Sale$50K–$100KSpouseOct 27, 2026Report
Sep 18, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfOct 12, 2026Report
Sep 17, 2026Thomas H. Kean, Jr. (R-NJ)Partial sale$1K–$15KSelfOct 30, 2026Report
Jul 30, 2026Richard McCormick (GA)Sale$1K–$15KSelfAug 14, 2026Report
Jul 17, 2026Mike Kelly (R-PA)Sale$1K–$15KSpouseAug 12, 2026Report
Jul 14, 2026Rick W. Allen (R-GA)Sale$15K–$50KSpouseAug 18, 2026Report
Jul 8, 2026Rick Larsen (D-WA)Sale$1K–$15KSelfJul 12, 2026Report
Jun 16, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfJul 2, 2026Report
Jun 12, 2026Richard McCormick (GA)Purchase$1K–$15KSelfJul 9, 2026Report
May 27, 2026Josh Gottheimer (D-NJ)Partial sale$1K–$15KJointJun 3, 2026Report
May 15, 2026Gilbert Ray Cisneros, Jr. (D-CA)Sale$1K–$15KSelfJun 8, 2026Report
May 12, 2026Julie Johnson (D-TX)Sale$1K–$15KJointJun 12, 2026Report
Apr 16, 2026Rick W. Allen (R-GA)Sale$15K–$50KSpouseJun 5, 2026Report
Mar 27, 2026Alan Armstrong (R-OK)Sale$15K–$50KSelfJul 21, 2026Report
Mar 24, 2026Laura Friedman (D-CA)Exchange$1K–$15KSelfApr 17, 2026Report
Mar 19, 2026Richard McCormick (GA)Purchase$1K–$15KSelfApr 7, 2026Report
Feb 10, 2026Gilbert Ray Cisneros, Jr. (D-CA)Partial sale$1K–$15KSelfMar 9, 2026Report
Jan 29, 2026Thomas H. Kean, Jr. (R-NJ)Purchase$1K–$15KSelfFeb 19, 2026Report
Dec 19, 2025Gilbert Ray Cisneros, Jr. (D-CA)Partial sale$1K–$15KSelfJan 12, 2026Report
Dec 18, 2025Julie Johnson (D-TX)Sale$1K–$15KJointJan 15, 2026Report
Dec 8, 2025Julia Letlow (R-LA)Sale$1K–$15KSelfJan 13, 2026Report
Dec 4, 2025Byron Donalds (R-FL)Sale$1K–$15KSelfJan 7, 2026Report
Dec 4, 2025Byron Donalds (R-FL)Sale$1K–$15KSpouseJan 7, 2026Report
Nov 18, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfDec 15, 2025Report
Nov 13, 2025Julie Johnson (D-TX)Partial sale$1K–$15KJointDec 11, 2025Report
Nov 5, 2025Richard McCormick (GA)Purchase$1K–$15KSelfDec 9, 2025Report
Oct 6, 2025Rick Larsen (D-WA)Purchase$1K–$15KSelfOct 16, 2025Report
Aug 14, 2025Julie Johnson (D-TX)Partial sale$1K–$15KJointSep 11, 2025Report
Jul 21, 2025Thomas H. Kean, Jr. (R-NJ)Purchase$1K–$15KSelfAug 20, 2025Report
Jul 18, 2025Josh Gottheimer (D-NJ)Partial sale$1K–$15KJointAug 11, 2025Report
Jul 10, 2025Lisa C. McClain (R-MI)Sale$1K–$15KSpouseAug 13, 2025Report
Jun 24, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseAug 13, 2025Report
May 12, 2025Jefferson Shreve (R-IN)Sale$50K–$100KSelfJun 22, 2025Report
Apr 21, 2025Bruce Westerman (R-AR)Sale$1K–$15KSelfMay 12, 2025Report
Mar 20, 2025Byron Donalds (R-FL)Purchase$1K–$15KSelfApr 14, 2025Report
Mar 20, 2025Byron Donalds (R-FL)Purchase$1K–$15KSpouseApr 14, 2025Report
Mar 6, 2025Josh Gottheimer (D-NJ)Partial sale$1K–$15KJointApr 10, 2025Report
Mar 3, 2025Bruce Westerman (R-AR)Purchase$1K–$15KSelfApr 16, 2025Report
Feb 24, 2025Shelley Moore Capito (R-WV)Partial sale$1K–$15KSpouseMar 6, 2025Report
Feb 13, 2025Josh Gottheimer (D-NJ)Purchase$1K–$15KJointMar 6, 2025Report
Jan 29, 2025Josh Gottheimer (D-NJ)Purchase$1K–$15KJointFeb 10, 2025Report
Jan 28, 2025Josh Gottheimer (D-NJ)Purchase$1K–$15KJointFeb 10, 2025Report
Jan 15, 2025Jared Moskowitz (D-FL)Sale$1K–$15KSelfFeb 10, 2025Report
Jan 15, 2025Jared Moskowitz (D-FL)Sale$1K–$15KChildFeb 10, 2025Report
Jan 6, 2025Emily Randall (D-WA)Sale$1K–$15KSpouseFeb 11, 2025Report
Dec 16, 2024Thomas H. Kean, Jr. (R-NJ)Purchase$1K–$15KSelfJan 22, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Abbott Laboratories company events

Abbott Laboratories filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 21, 2026.

  1. Oct 21, 2026AnnouncementFiled as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing that it plans to separate its global nutrition business into an independent, publicly traded company. Filing
  2. Oct 21, 2026ResultsReleased financial results. Filing
  3. Aug 20, 2026AnnouncementAs previously reported in Abbott’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, Abbott is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis… Filing
  4. Jul 16, 2026ResultsReleased financial results. Filing
  5. Apr 27, 2026LeadershipKevin Conroy was named to the Abbott Laboratories’ Board of Directors. Filing
  6. Apr 17, 2026AnnouncementAs previously disclosed in Abbott’s Annual Reports on Form 10-K for the fiscal years ended December 31, 2024 and December 31, 2025, six shareholder derivative lawsuits have been pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation, before… Filing
  7. Apr 16, 2026ResultsReleased financial results. Filing
  8. Mar 23, 2026AnnouncementAbbott Laboratories, an Illinois corporation, completed the acquisition of Exact Sciences Corporation, a Delaware corporation, pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025, by and among Abbott, Exact Sciences and Badger Merger Sub I, Inc., a Delaware corporation and a… Filing
  9. Mar 9, 2026AgreementAbbott Laboratories completed the public offering and issuance of $20 billion of senior notes, consisting of $1 billion of its Floating Rate Notes due 2029, $2.25 billion of its 3.700% Notes due 2029, $2.5 billion of its 4.000% Notes due 2031, $2.75 billion of its 4.300% Notes due 2033, $3.75… Filing
  10. Feb 26, 2026AgreementAbbott Laboratories entered into a pricing agreement, dated February 23, 2026, by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein, pursuant… Filing
  11. Feb 20, 2026RulesChanged its bylaws or articles. Filing
  12. Jan 22, 2026ResultsReleased financial results. Filing
  13. Dec 12, 2025LeadershipNita Ahuja, M.D. was named to the Abbott Laboratories’ Board of Directors. Filing
  14. Nov 20, 2025AgreementAbbott Laboratories, an Illinois corporation, entered into an Agreement and Plan of Merger with Exact Sciences Corporation, a Delaware corporation, and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

How Abbott Laboratories makes money

Medical Devices brought in half of Abbott Laboratories's revenue ($21.4B of $44.3B) in 2025. Diagnostic Products was next, at 20%.

By business segment, 2025

Medical Devices$21.4B · 48%
Diagnostic Products$8.9B · 20%
Nutritional Products$8.5B · 19%
Established Pharmaceutical Products$5.5B · 12%

By region, 2025

United States$17.1B · 39%
All Other Countries$16B · 36%
Germany$2.8B · 6%
China$1.9B · 4%
Switzerland$1.9B · 4%
India$1.9B · 4%
Japan$1.5B · 3%
United Kingdom$1.3B · 3%

From Abbott Laboratories's annual report (10-K) for the year ended Dec 31, 2025, filed Feb 20, 2026. The company chooses how to group its revenue, so the parts differ from one company to the next. Read the filing · How the biggest companies make money

Abbott Laboratories financials

Famous investors that hold ABT

10 of the 50 well-known investors we track reported holding ABT in their latest 13F filing. The largest position is Jeremy Grantham's, worth $886M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jeremy Grantham · GMOQ3 20268.97M$886M1.9%+2%
Israel Englander · Millennium ManagementQ3 20262.10M$207M0.2%-42%
Steve Cohen · Point72 Asset ManagementQ3 20261.84M$182M0.3%+19%
Ken Griffin · Citadel AdvisorsQ3 20261.70M$168M0.1%-80%
Ken Fisher · Fisher Asset ManagementQ3 2026467,019$46.2M0.0%-8%
Jim Simons · Renaissance TechnologiesQ3 2026458,466$45.3M0.1%-33%
Ray Dalio · Bridgewater AssociatesQ3 202655,789$5.5M0.0%-7%
George Soros · Soros Fund ManagementQ3 202644,750$4.4M0.1%No change
Paul Tudor Jones · Tudor Investment CorpQ3 202616,099$1.6M0.0%-98%
Tom Russo · Gardner Russo & QuinnQ3 202611,510$1.1M0.0%No change

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Abbott Laboratories (ABT) stock

Who owns the most ABT stock?

The largest reported owner of Abbott Laboratories (ABT) is BlackRock, Inc., with 8.8% of the company. In total, 2,951 funds and institutions reported holding ABT at the end of Q2 2026, together about 80% of the shares. See the largest owners.

Are ABT insiders buying or selling?

In the last 12 months, ABT insiders reported 6 open-market purchases worth $4.4M and 12 sales worth $47.9M. The latest trade was on Nov 5, 2026. See every trade.

What is the short interest in ABT?

As of Oct 30, 2026, 19.06M ABT shares were sold short, 1.1% of the shares outstanding, up 9.6% from the report before. At the average daily volume of 9.96M shares, buying them all back would take about 1.9 trading days (days to cover). See the history.

Have members of Congress traded ABT?

Yes. 19 members of Congress reported 17 purchases and 28 sales of ABT since Nov 17, 2024. The latest was reported on Oct 30, 2026. See the trades.

How does Abbott Laboratories make money?

Medical Devices brought in half of Abbott Laboratories's revenue ($21.4B of $44.3B) in 2025. Diagnostic Products was next, at 20%. See the full split.

Which famous investors hold ABT?

10 of the 50 well-known investors we track reported ABT in their latest 13F filing, including Jeremy Grantham, Israel Englander, Steve Cohen. The largest position is worth $886M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.